AlphAIAlphAI — Financial news for AI agents
rttnews.comNOV 22 min read$JNJ

J&J's Javelin Meets Pivotal Coronary Study Goals; Highlights Impella Survival Data At TCT

Johnson & Johnson (JNJ) reported that its Shockwave Javelin coronary catheter met primary endpoints in the FORWARD CAD study, with 93.6% successful lesion crossing and 93.4% safety. The study involved 158 patients. Separately, J&J shared favorable Impella data from three analyses, showing low mortality rates. JNJ closed at $273.20, down 0.73%.

Original reporting
rttnews.com
Published Nov 2, 2026, 5:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 5:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

The trial data provides the first public efficacy and safety numbers for Javelin, potentially influencing investor perception of J&J's cardiovascular pipeline.

02

Market read

Positive early‑stage data could modestly support J&J's stock and benefit related med‑tech peers.

03

What to watch

Regulatory approval timeline and reimbursement uncertainty could temper price reaction.

Relevance 8/10Novelty 8/10Timing: same-day release

Background

The article reports J&J's presentation at the 2026 TCT congress of pivotal trial results for its Shockwave Javelin IVL catheter and recent Impella registry outcomes.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

J&J disclosed that its investigational Javelin IVL catheter met primary effectiveness (93.6%) and safety (93.4%) endpoints in the pivotal FORWARD CAD study.

Expected impact

modest upside as market prices in the favorable safety and efficacy results

Evidence & confidence

First‑time disclosure of pivotal trial success; investors often reward such data, though the device remains investigational.

Market effects

Sector

May boost outlook for intravascular lithotripsy and broader cardiovascular device sector.

Regional

U.S. and U.K. markets could see slight gains in med‑tech stocks.

Global

Limited to healthcare investors; no broad macro effect.

Counterpoint

What could challenge this read

Data, while positive, still reflects a single‑arm study; commercial rollout risk remains high.

Key entities

  • company
    Johnson & Johnson

    US‑listed healthcare conglomerate reporting trial results.

  • clinical_trial
    FORWARD CAD study

    Pivotal trial evaluating Javelin IVL catheter.

Read at source← All news

StoryJohnson & Johnson reports lower mortality with Impella heart pumps and positive Javelin catheter trial results

Also covered by

2 outlets

Related articles

NOV 2
$JNJMedAI 8/10

Johnson & Johnson’s Javelin Catheter Met Both Trial Goals and Its Impella Data Pushed Back on a Negative Study. Here’s What It Doesn’t Settle

Johnson & Johnson (JNJ) reported positive results for its Javelin catheter, meeting both primary goals in a pivotal study. Impella heart pump data showed lower death rates than a previous negative study. Javelin is still under FDA review, and Impella's recovery depends on future trials. JNJ's cardiovascular unit saw a sales decline, with Impella contributing 1.6% of total revenue. Analysts project a ~25% total return for JNJ stock.

finance.yahoo.com3 min
NOV 2
$JNJMed

TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland

Johnson & Johnson's TREMFYA (guselkumab) has been approved for reimbursement in Ireland for treating moderately to severely active Crohn’s disease and ulcerative colitis. The approval is based on Phase 3 trials showing significant clinical remission rates. According to the company, it offers a novel dual mechanism of action and improved outcomes for patients.

imt.ie2 min
NOV 2
$JNJMed

J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3

Johnson & Johnson (J&J) presented data at a symposium showing lower mortality rates in high-risk PCI patients using Impella heart pumps compared to the CHIP-BCIS3 trial. Three analyses, involving 1,379 patients, reported 30-day mortality rates of 6.1% and 4.7%, and 90-day rates of 6.5%. J&J's heart recovery chief medical officer highlighted the importance of device usage and patient selection. The company continues studying Impella, with PROTECT IV trial results expected in 2027.

medicaldevice-network.com2 min
NOV 2
$JNJHigh

PROTEUS: Perioperative Apalutamide Plus ADT Improves EFS in High-Risk Locally Advanced Prostate Cancer

A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.

endocrinologyadvisor.com2 min